Thienamycin was shown to be a more potent inhibitor than ampicillin of the enzyme peptidoglycan transpeptidase from Escherichia coli.
f8-Lactam antibiotics kill bacteria by inhibiting reactions involved in the final stages of cell wall biosynthesis (1, 2) . It is generally believed that a membrane-bound transpeptidase, which catalyzes the cross-linking of neighboring aminoacid side chains during cell wall peptidoglycan synthesis, is a major target for ,-lactam action and that inhibition of this enzyme leads to cell death (15, 16). Furthermore, all ,B-lactams antibiotics so far investigated have been shown to bind irreversibly to one or more of six penicillinbinding proteins (PBPs) found in the cytoplasmic membrane of Escherichia coli (10) . Although the roles of all six PBPs have not been fully elucidated, it is assumed that one or more are the targets for the lethal action of penicillins and cephalosporins (10) .
Thienamycin is a novel, broad-spectrum, highly potent /3-lactam antibiotic obtained from cultures of Streptomyces cattleya (14) , and it is known to bind with high affinity to all six E. coli PBPs (11) . It is believed that a component of PBP 1 has the properties expected of the enzyme peptidoglycan transpeptidase (11, 13) . Thienamycin binds to PBP 1 with higher affinity than does almost any other ,B-lactam antibiotic so far studied (10, 11) . However, no direct evidence that thienamycin actually inhibits the transpeptidase has so far been reported. We have produced evidence demonstrating transpeptidase inhibition by thienamycin and have shown that the potency of thienamycin as a transpeptidase inhibitor is commensurate with its antibacterial activity.
The transpeptidase assay system used was that of Mirelman et al. (6) 
Simultaneous incorporation of these by ETB proceeds via macromolecular peptidoglycan precursors which are then cross-linked to preexisting cell wall exclusively by penicillin-sensitive transpeptidation (6 and thienamycin on the transpeptidase reaction were determined and expressed as a percentage of the control reaction (Fig. 1) . No significant inhibition occurred at ampicillin concentrations below 0.5,ug/ml and thienamycin concentrations below 0.05 ,ug/ml. It is clear from Fig. 1 that thienamycin is a potent transpeptidase inhibitor, having a 50% inhibitory concentration of 0.23 ug/ml compared with 1.8 ug/ml for ampicillin, showing theinamycin to be about eight times more potent than ampicillin. Minimal inhibitory concentrations of thienamycin and ampicillin against E. coli 146 were also determined by using an agar dilution technique. E. coli 146 was grown in Iso-Sensitest broth (Oxoid Ltd.) at 370C for 18 h. The culture was then diluted 100-fold in broth and inoculated onto Iso-Sensitest agar (Oxoid Ltd.) con [7, 8] ).
It is reasonable to suppose that the enzyme peptidoglycan transpeptidase is a target for thienamycin action, as it is for other ,B-lactam antibiotics (2, 15, 16 ). This is not necessarily the only important target site, however. For example, there is evidence that thienamycin binds with highest affinity to PBP 2 (11), which is not the transpeptidase, and that reduction of this affinity alone, by mutation, leads to a decrease in susceptibility of the organism to thienamycin (9) . No enzyme activity has yet been associated with PBP 2.
In E. coli, a component of PBP 1 has the properties which might be expected of the enzyme peptidoglycan transpeptidase (11, 13) . Thienamycin binds strongly to PBP 1, and the results of our experiments indicate that thienamycin strongly inhibits the transpeptidase enzyme.
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